See more : Red Sky Energy Limited (ROG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Leap Therapeutics, Inc. (LPTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Leap Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Zhejiang Cayi Vacuum Container Co., Ltd. (301004.SZ) Income Statement Analysis – Financial Results
- Xvivo Perfusion AB (publ) (0RKL.L) Income Statement Analysis – Financial Results
- Connexus Corporation (CNXS) Income Statement Analysis – Financial Results
- Blue Jet Healthcare Limited (BLUEJET.BO) Income Statement Analysis – Financial Results
- Element Nutritional Sciences Inc. (ELMT.CN) Income Statement Analysis – Financial Results
Leap Therapeutics, Inc. (LPTX)
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.50M | 1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 427.00K | 415.00K | 0.00 | 0.00 | 776.00K | 49.00K | 48.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -427.00K | -415.00K | 1.50M | 1.50M | -776.00K | -49.00K | -48.00K | -25.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.23M | 44.97M | 32.16M | 20.42M | 24.37M | 21.07M | 22.50M | 23.29M | 15.37M | 15.54M | 9.30M | 7.17M |
| General & Administrative | 13.81M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Selling & Marketing | -427.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.38M | 11.80M | 10.77M | 9.62M | 9.09M | 8.92M | 9.85M | 4.23M | 5.72M | 4.71M | 4.57M | 1.51M |
| Other Expenses | 0.00 | -2.05M | -1.23M | -231.00K | -132.00K | 756.00K | 0.00 | 3.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Cost & Expenses | 87.04M | 54.71M | 41.70M | 29.81M | 33.32M | 30.00M | 32.35M | 27.52M | 21.09M | 20.25M | 13.87M | 8.68M |
| Interest Income | 4.03M | 925.00K | 9.00K | 93.00K | 313.00K | 447.00K | 170.00K | 2.00K | 156.00K | 40.00K | 94.00K | 102.00K |
| Interest Expense | 0.00 | 54.00K | 41.00K | 39.00K | 23.00K | 19.00K | 121.00K | 1.23M | 18.00K | 4.37M | 0.00 | 0.00 |
| Depreciation & Amortization | 427.00K | 415.00K | 556.00K | 668.00K | 776.00K | 49.00K | 48.00K | 25.00K | 474.00K | 657.00K | 640.00K | 649.00K |
| EBITDA | -80.99M | -53.98M | -40.01M | -26.81M | -32.10M | -23.05M | -29.71M | -24.37M | -11.92M | -19.73M | -13.23M | -6.98M |
| EBITDA Ratio | 0.00% | 0.00% | -2,679.40% | -1,881.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.04M | -56.76M | -41.43M | -28.54M | -33.45M | -30.75M | -32.35M | -27.52M | -21.09M | -20.92M | -13.87M | -8.80M |
| Operating Income Ratio | 0.00% | 0.00% | -2,761.73% | -1,902.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.63M | 2.31M | 815.00K | 1.02M | 548.00K | 7.63M | 2.47M | 1.89M | 9.04M | -4.50M | -4.31M | 1.04M |
| Income Before Tax | -81.41M | -54.45M | -40.61M | -27.52M | -32.90M | -23.12M | -29.88M | -25.63M | -20.95M | -25.42M | -18.18M | -7.76M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,707.40% | -1,834.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 147.00K | -24.00K | -2.00K | -3.00K | 20.00K | -157.00K | 4.35M | 152.00K | 31.00K | 149.00K | 0.00 |
| Net Income | -81.41M | -54.60M | -40.59M | -27.51M | -32.90M | -23.14M | -29.73M | -25.63M | -21.10M | -25.45M | -18.32M | -7.76M |
| Net Income Ratio | 0.00% | 0.00% | -2,705.80% | -1,834.27% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.36 | -32.45 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EPS Diluted | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.05 | -32.35 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| Weighted Avg Shares Out | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.41M | 916.18K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
| Weighted Avg Shares Out (Dil) | 20.45M | 11.32M | 8.58M | 5.93M | 2.26M | 1.44M | 918.86K | 939.24K | 1.71M | 1.19M | 744.40K | 744.40K |
Why Are Leap Therapeutics Shares Trading Higher On Monday?
Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company's presentation of new data from the first-line cohort of the DisTinGuish study. The Phase 2a trial is evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01,...
LPTX Stock: Why It Increased Today
The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased over 20% pre-market. This is why it happened.
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress
CAMBRIDGE, Mass., Sept. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase...
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Leap Therapeutics, Inc. (LPTX) Reports Q2 Loss
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of 7.69% and 0.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation
CAMBRIDGE, Mass., Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.
Leap Therapeutics to Present at the ESMO 2021 Virtual Congress
CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's...
Down 19.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Leap Therapeutics, Inc. (LPTX)
Leap Therapeutics, Inc. (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
Source: https://incomestatements.info
Category: Stock Reports